Pharmacy Comparison Table

Why this check exists at all

An FDA-approved product has been reviewed before marketing and is made under a federal quality system with supply-chain traceability. A compounded preparation has not been through that review. Its assurance comes from the pharmacy, the state board that licenses it and, at good operations, batch testing for sterility and potency.

That is a legitimate framework rather than a loophole, and it moves verification work onto the patient. This page is one part of that work.

What a programme's answer tells you

Fewer than a fifth of the 20 priced programmes name a dispensing pharmacy before purchase. The ones that do are not systematically more expensive, which undercuts the usual explanation that disclosure costs money.

A name and a licence number is the good answer. A category is incomplete but honest about what it withholds. A deflection about proprietary partnerships is itself the answer.

Where this sits against price

Disclosure and price are close to independent in this market. Some of the cheapest programmes publish the most and some of the dearest publish almost nothing.

Verify separately from comparing cost, and let a failure here disqualify a programme regardless of the number attached to it. A saving of a few hundred dollars a year does not compensate for not knowing who made what you are injecting weekly.

Reading this against the rest of the decision

This sits inside a decision with three parts: what you pay at the dose you hold, who makes what you are injecting, and what happens if you stop. Most published guidance covers the first and treats the other two as footnotes.

They are not footnotes. A price advantage of a few hundred dollars a year is erased by one interrupted month, and an interruption is a clinical event rather than an inconvenience — semaglutide takes sixteen weeks to re-titrate from the starter dose.

Which is why this section exists separately from the pricing pages, and why the verification steps on it are worth completing even when the programme you are considering is the cheapest on the site.

What to do with this before you enrol

Turn it into two or three questions you can send in an email. Anything here that cannot be converted into a question a programme could answer in writing is context rather than a check, and context does not protect you.

The programmes that answer promptly and specifically are, in our reading of the public record, rarely the ones patients later write about. That is a weak signal rather than evidence, but it costs nothing to collect and it arrives before your money does.

If a programme declines to answer, that is an answer. The market currently offers 20 priced alternatives, the cheapest verified at $145 a month all-in at a maintenance dose.

The failure mode this section guards against

Choosing a programme on a number that describes a different situation than yours. An entry price when you will hold maintenance. A medication figure when a membership applies. A promotional rate when you will renew.

Each error is small alone and they compound in one direction, which is why the cheapest-looking option in most published comparisons is the one most likely to be mis-stated. Priced correctly the cheapest verified route sits at $145 a month all-in at a 2.4 mg maintenance dose.

Why we publish the working rather than a verdict

A single recommendation reads better and acts worse, because it hides the weighting. Two readers with different maintenance doses, different coverage and different tolerance for commitment should not receive the same answer.

So the tables carry the inputs and every ranking states its sort key. Disagree with our weighting and you can take the file and weight it yourself — which is what publishing it is for.

The number most people get wrong

The month-six figure. Almost everyone budgets from the first month, which on semaglutide describes four weeks at 0.25 mg — roughly 1 mg of active drug against the 9.6 mg a maintenance month delivers.

Ten of your first twelve months are spent at or near maintenance. A ranking sorted on the advertised month is sorting on about eight per cent of your year, and on a dose-scaled programme those are different numbers entirely.

Run the first-year calculator at the dose you expect to hold. It takes under a minute and it reorders the market for most people.

What a year of this actually looks like

Four weeks at 0.25 mg, four at 0.5 mg, four at 1 mg, four at 1.7 mg, then 2.4 mg for the remainder. Sixteen weeks of titration if nothing is repeated, and repeats are common rather than exceptional.

Budget two extra months at a lower tier and treat anything better as upside. Fix a weekly injection day, record dose and date, and diary the renewal date if an introductory rate applies — the reversion is where most complaints in this category begin.

Putting pharmacy comparison table in proportion

It is one input into a decision with three parts: what you pay at the dose you hold, who makes what you inject, and what happens if you stop. Weighting one to the exclusion of the others is how people end up on a cheap programme they abandon in month nine.

The frame: 20 programmes publish a capturable price, spanning $145 to $324 a month all-in at a 2.4 mg maintenance dose. 4 charge a mandatory recurring fee. 6 name the dispensing pharmacy before purchase.

What good looks like

A figure at a named dose, the pharmacy named, cancellation terms published before payment, and a plain statement that a compounded preparation is not FDA-approved. Four things, all cheap to publish, and a minority does all four.

The cheapest verified route sits at $145 a month, which establishes that disclosure and low price are not in tension.

What to ask before you pay

Five questions, all answerable in a short email, all before a medical history changes hands: the total at a maintenance dose including every fee; which pharmacy fills it; whether the prescriber is licensed in your state; the notice period to cancel and what is refundable; and which form of the active ingredient the pharmacy compounds from.

None requires clinical training to evaluate. The speed and specificity of the reply tells you how the operation is run, and it arrives before your money does.